Combined analysis of phase III trials evaluating [99mTc] tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma

Annals of Surgical Oncology

Volumn 20, Issue 2, 2013, Pages 680-688

  Sondak, Vernon K ^a   King, Dennis W ^b   Zager, Jonathan S ^a   Schneebaum, Schlomo ^c   Kim, Julian ^d   Leong, Stanley P L ^e   Faries, Mark B ^f   Averbook, Bruce J ^g   Martinez, Steve R ^h   Puleo, Christopher A ^a   Messina, Jane L ^a   Christman, Lori ^b   Wallace, Anne M ⁱ  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b STATKING Clinical Services   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f JOHN WAYNE CANCER INSTITUTE   (United States)

^g METROHEALTH MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFINE BLUE; ISOSULFAN BLUE; TILMANOCEPT TC 99M;

ADULT; AGED; ARTICLE; ASTHMA; BRADYCARDIA; CELLULITIS; CUTANEOUS MELANOMA; EXCISION; FAINTNESS; FEMALE; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; INJECTION SITE PAIN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; SENTINEL LYMPH NODE; SEROMA; TACHYCARDIA;

ADULT; AGED; AGED, 80 AND OVER; COLORING AGENTS; DEXTRANS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOPERATIVE CARE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MANNANS; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TECHNETIUM TC 99M PENTETATE; YOUNG ADULT;

EID: 84875758345     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2612-z     Document Type: Article

References (23)

1. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
2. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011;364:1738-45.
3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-9.
4. Liu Y, Truini C, Ariyan S. A randomized study comparing the effectiveness of methylene blue dye with lymphazurin blue dye in sentinel lymph node biopsy for the treatment of cutaneous melanoma. Ann Surg Oncol. 2008;15:2412-7.
5. Neves RI, Reynolds BQ, Hazard SW, Saunders B, Mackay DR. Increased post-operative complications with methylene blue versus lymphazurin in sentinel lymph node biopsies for skin cancers. J Surg Oncol. 2011;103:421-5.
6. Billinghurst MW, Jette D. Colloidal particle-size determination by gel filtration. J Nucl Med. 1979;20:133-7.
7. Hung JC, Wiseman GA, Wahner HW, Mullan BP, Taggart TR, Dunn WL. Filtered technetium-99m-sulfur colloid evaluated for lymphoscintigraphy. J Nucl Med. 1995;36:1895-901.
8. Tafra L, Chua AN, Ng PC, Aycock D, Swanson M, Lannin D. Filtered versus unfiltered technetium sulfur colloid in lymphatic mapping: a significant variable in a pig model. Ann Surg Oncol. 1999;6:83-7.
9. Uhara H, Yamazaki N, Takata M, et al. Applicability of radiocolloids, blue dyes and fluorescent indocyanine green to sentinel node biopsy in melanoma. J Dermatol. 2012;39:336-8.
10. Liu LC, Parrett BM, Jenkins T, et al. Selective sentinel lymph node dissection for melanoma: importance of harvesting nodes with lower radioactive counts without the need for blue dye. Ann Surg Oncol. 2011;18:2919-24.
11. Pharmalucence press release. http://www.pharmalucence.com/content.php? cont=129. Accessed 25 July 2011.
12. Vera DR, Wallace AM, Hoh CK, Mattrey RF. A synthetic macromolecule for sentinel node detection: [99mTc]DTPA-mannosyl-dextran. J Nucl Med. 2001;42:951-9.
13. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med. 1990;172:1785-94.
14. McGreal EP, Miller JL, Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol. 2005;17:18-24.
15. Vera DR, Wisner ER, Stadalnik RC. Sentinel node imaging via a nonparticulate receptor-binding radiotracer. J Nucl Med. 1997; 38:530-5.
16. Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531-8.
17. Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg Oncol. 2007;14:913-21.
18. Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849-53.
19. Leong SPL, Kim J, Ross MI, et al. A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer. Ann Surg Oncol. 2011;18:961-9.
20. Wallace AM, Hoh CK, Limmer KK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol. Nucl Med Biol. 2009;36:687-92.
21. Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479-87.
22. Vermeeren L, van der Ploeg IM, Olmos RA, et al. SPECT/CT for preoperative sentinel node localization. J Surg Oncol. 2010;101:184-90.
23. Veenstra HJ, Vermeeren L, Valdés Olmos RA, Nieweg OE. The additional value of lymphatic mapping with routine SPECT/CT in unselected patients with clinically localized melanoma. Ann Surg Oncol. 2012;19:1018-23.